



Appl. No. : 09/852,910  
Applicant : Annette GILCHRIST et al.  
Filed : May 11, 2001  
TC/A.U. : 1639  
Examiner : Teresa D. Wessendorf  
Docket No. : 2661-101  
Customer No. : 06449  
Confirmation No. : 4758

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent  
and Trademark Office  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith copies of publications that the Office may wish to consider in examination of the subject application. The publications are listed on the attached form PTO-1449.

Pursuant to 37 C.F.R. § 1.17(p), a check, which includes the \$180.00 fee, is attached to the Fee Transmittal. The Commissioner is authorized to charge any additional fees or credit any overpayment to Deposit Account No. 02-2135. An additional copy of this document is enclosed.


04/05/2005 SZENDIE1 00000056 09852910

01 FC:1806

180.00 OP


Respectfully submitted,

By

  
Martha Cassidy  
Attorney for Applicants  
Registration No. 44,066  
ROTHWELL, FIGG, ERNST & MANBECK, p.c.  
Suite 800, 1425 K Street, N.W.  
Washington, D.C. 20005  
Telephone: (202) 783-6040

Enclosure(s) :  
PTO-1449 Form  
References (21)


2661-101.ids4.wpd

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> 				<i>Complete if Known</i>	
				Application Number	09/852,910
				Filing Date	May 11, 2001
				First Named Inventor	Annette GILCHRIST et al.
				Group Art Unit	1639
				Examiner Name	Wessendorf, Teresa D.
				Confirmation No.	4758
Sheet	1	of	2	Attorney Docket Number	2661-101

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
	1	ARIS et al., "Structural requirements for the stabilization of metarhodopsin II by the C terminus of the $\alpha$ subunit of Transducin," <i>J. Biol. Chem.</i> , 276(4):2333-2339, 2001.		
	2	BUCK et al., "Role of dynamic interactions in effective signal transfer for G $\beta$ stimulation of phospholipase C- $\beta$ 2," <i>J. Biol. Chem.</i> , 277(51):49707-49715, 2002.		
	3	CHEADLE et al., "Identification of a Src SH3 domain binding motif by screening a random phage display library," <i>J. Biol. Chem.</i> , 269(39):24034-24039, 1994.		
	4	COPELAND, Robert A., "Mechanistic considerations in high-throughput screening," <i>Analytical Biochemistry</i> , 320:1-12, 2003.		
	5	CULL et al., "Screening for receptor ligands using large libraries of peptides linked to the C terminus fo the <i>lac</i> repressor," <i>Proc. Natl. Acad. Sci.</i> , 89:1865-1869, 1992.		
	6	CWIRLA et al., "Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine," <i>Science</i> , 276:1696-1699, June 13, 1997.		
	7	DANI, Maria, "Peptide display libraries: design and construction," <i>J. Of Receptor &amp; Signal Transduction Research</i> , 21(4):469-488, 2001.		
	8	FRANCKEN et al., "Human 5-hydroxytryptamine <sub>5A</sub> receptors activate coexpressed G <sub>i</sub> and G <sub>o</sub> proteins in <i>Spodoptera frugiperda</i> 9 cells," <i>Mol. Pharm.</i> , 57:1034-1044, 2000.		
	9	GILCHRIST et al., "Use of peptides-on-plasmids combinatorial library to identify high-affinity peptides that bind rhodopsin," <i>Methods in Enzymology</i> , 315:388-404, 2000.		
	10	GLASS et al., "Agonist selective regulation of G proteins by cannabinoid CB <sub>1</sub> and CB <sub>2</sub> receptors," <i>Mol. Pharmacol.</i> , 56:1362-1369, 1999.		
	11	HALL, David A., "Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation," <i>Mol. Pharmacol.</i> , 58:1412-1423, 2000.		
Examiner Signature				Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> 				Complete if Known	
				Application Number	09/852,910
				Filing Date	May 11, 2001
				First Named Inventor	Annette GILCHRIST et al.
				Group Art Unit	1639
				Examiner Name	Wessendorf, Teresa D.
				Confirmation No.	4758
Sheet	2	of	2	Attorney Docket Number	2661-101

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
	12	KAY et al., "Screening phage-displayed combinatorial peptide libraries," <i>Methods</i> , 24:240-246, 2001.		
	13	KOIVUNEN et al., "Identification of receptor ligands with phage display peptide libraries," <i>J. Nucl. Med.</i> , 40:883-888, 1999.		
	14	MARTIN et al., "Potent peptide analogues of a G protein receptor-binding region obtained with a combinatorial library," <i>J. Biol. Chem.</i> , 271(1):361-366, 1996.		
	15	NEUBIG et al., "International union of pharmacology committee on receptor nomenclature and drug classification. XXXVIII. Update on terms and symbols in quantitative pharmacology," <i>Pharmacol. Rev.</i> , 55:597-606, 2003.		
	16	RODI et al., "Phage-display technology-finding a needle in a vast molecular haystack," <i>Current Opinion in Biotechnology</i> , 10:87-93, 1999.		
	17	SCHATZ et al., "Screening of peptide libraries linked to <i>lac</i> receptor," <i>Methods in Enzymology</i> , 267:171-191, 1996.		
	18	SUNDBERG, Steven A., "High-throughput and ultra-high-throughput screening: solution- and cell-based approaches," <i>Current Opinion in Biotechnology</i> , 11:47-53, 2000.		
	19	SZARDENINGS et al., "New highly specific agonistic peptides for human melanocortin MC <sub>1</sub> receptor," <i>Peptides</i> , 21:239-243, 2000.		
	20	WINDH et al., "Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G <sub>i</sub> , G <sub>q</sub> , and G12 families of heterotrimeric G Proteins," <i>J. Biol. Chem.</i> , 274(39):27351-27358, 1999.		
	21	ZWICK et al., "Phage-displayed peptide libraries," <i>Current Opinion in Biotechnology</i> , 9:427-436, 1998.		
Examiner Signature				Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code.